ResMed launches new sleep breathing devices, platform

ResMed (ASX:RMD) has launched a line of new sleep-disordered breathing therapy devices, as well as a new connected patient care platform for treating the condition.

The company has unveiled its new AirSense 10 line of positive airway pressure (PAP) devices.

The new line includes two new continuous PAP devices that introduce new functionality including remote device settings and changes, integrated heated humidification and a streamlined user interface.

The AirSense 10 line also includes the only US FDA-approved device for providing specialised sleep apnoea therapy for women, using the new algorithm ResMed unveiled in May.

When taken together, the products form the cornerstone of ResMed’s new Air Solutions platform, which aims to address the needs of clinicians and patients undergoing sleep-disordered breathing therapy.

AirSolutions has components that span from diagnosis to treatment, compliance management and patient engagement.

These components include ResMed’s AirFit line of nasal pillows, a patient engagement software suite dubbed myAir, the AirView monitoring and compliance management system and the ApneaLink Air home sleep testing device.

ResMed (ASX:RMD) shares were trading 0.18% higher at $5.55 as of around 1 pm on Tuesday.